BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 18953554)

  • 1. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization.
    Han YS; Lee JE; Jung JW; Lee JS
    Graefes Arch Clin Exp Ophthalmol; 2009 Apr; 247(4):541-8. PubMed ID: 18953554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
    Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis.
    Hosseini H; Nejabat M; Mehryar M; Yazdchi T; Sedaghat A; Noori F
    Clin Exp Ophthalmol; 2007 Nov; 35(8):745-8. PubMed ID: 17997779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
    Kim TI; Kim SW; Kim S; Kim T; Kim EK
    Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
    Yoo AR; Chung SK
    Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.
    Lee SY; Kim DK; Cho JH; Koh JY; Yoon YH
    Arch Ophthalmol; 2008 Jul; 126(7):953-8. PubMed ID: 18625942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
    Hurmeric V; Mumcuoglu T; Erdurman C; Kurt B; Dagli O; Durukan AH
    Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.
    Kang S; Chung SK
    Cornea; 2010 Feb; 29(2):192-6. PubMed ID: 20098156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subconjunctival bevacizumab for corneal neovascularization.
    Erdurmus M; Totan Y
    Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1577-9. PubMed ID: 17458556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo.
    Kwon YS; Hong HS; Kim JC; Shin JS; Son Y
    Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):454-60. PubMed ID: 15671269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.
    Dratviman-Storobinsky O; Avraham-Lubin BCR; Hasanreisoglu M; Goldenberg-Cohen N
    Mol Vis; 2009 Nov; 15():2326-38. PubMed ID: 19936307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effect of curcumin on corneal neovascularization in vitro and in vivo.
    Bian F; Zhang MC; Zhu Y
    Ophthalmologica; 2008; 222(3):178-86. PubMed ID: 18497527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xanthatin inhibits corneal neovascularization by inhibiting the VEGFR2‑mediated STAT3/PI3K/Akt signaling pathway.
    Shen M; Zhou XZ; Ye L; Yuan Q; Shi C; Zhu PW; Jiang N; Ma MY; Yang QC; Shao Y
    Int J Mol Med; 2018 Aug; 42(2):769-778. PubMed ID: 29717775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of bevacizumab on corneal neovascularization in rabbits.
    Kim WJ; Jeong HO; Chung SK
    Korean J Ophthalmol; 2010 Aug; 24(4):230-6. PubMed ID: 20714387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subconjunctival bevacizumab for corneal neovascularization.
    Doctor PP; Bhat PV; Foster CS
    Cornea; 2008 Oct; 27(9):992-5. PubMed ID: 18812760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subconjunctival bevacizumab injection for corneal neovascularization.
    Bahar I; Kaiserman I; McAllum P; Rootman D; Slomovic A
    Cornea; 2008 Feb; 27(2):142-7. PubMed ID: 18216566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
    Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
    Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
    Avisar I; Weinberger D; Kremer I
    Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis.
    Tunik S; Nergiz Y; Keklikci U; Akkus M
    Graefes Arch Clin Exp Ophthalmol; 2012 Aug; 250(8):1161-7. PubMed ID: 22527313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of trehalose on VEGF-stimulated angiogenesis and myofibroblast proliferation: implications for glaucoma filtration surgery.
    Takeuchi K; Nakazawa M; Ebina Y
    Invest Ophthalmol Vis Sci; 2011 Sep; 52(9):6987-93. PubMed ID: 21778273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.